本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、募集资金基本情况 根据中国证券监督管理委员会于2018年12月5日签发的证监许可[2018]1843号文《关于核准深圳市尚荣 医疗股份有限公司公开发行可转换公司债券的批复》深圳市尚荣医疗股份有限公司（以下简称"公 司"或"尚荣医疗"）获准社会公开发行面值总额75,000万元的可转换公司债券，期限6年。公开发行可转 换公司债券应募集资金人民币750,000,000.00元，发行价格为每张人民币100.00元，募集资金总额为人民 币750,000,000.00元。本次发行可转换公司债券募集资金总额扣除保荐承销费用不含税金额14,150,943.40 元，其他发行费用不含税金额2,502,830.20元，实际募集资金净额为人民币733,346,226.40元，上述资金 于2019年2月20日到位，业经大华会计师事务所（特殊普通合伙）验证并出具大华验字[2019]000067号 验资报告。公司对募集资金采取了专户存储，并与专户银行、保荐机构签订了募集资金专户存储三方监 管协议。 本次发行可转换公司债券募集资金总额为人 ...

《关于公开发行可转换公司债券募集资金专户销户完成的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月27日收盘，尚荣医疗（002551）报收于3.86元，较前一交易日上涨0.26%，最新总市值 为32.64亿元。该股当日开盘3.86元，最高3.89元，最低3.82元，成交额达3839.69万元，换手率为 1.63%。 公司近日发布公告称，深圳市尚荣医疗股份有限公司于2019年2月20日完成公开发行可转换公司债券， 募集资金总额7.5亿元，实际募集资金净额7.33亿元，用于"高端医疗耗材产业化项目"。公司已于2025年 8月23日和9月12日经董事会及股东大会审议通过终止该项目，并将剩余募集资金约3.59亿元永久补充流 动资金。截至近日，5个募集资金专户资金已全部支出完毕，相关专户已完成注销，三方监管协议同步 终止。 最新公告列表 ...

Core Viewpoint - Shenzhen Shangrong Medical (002551) announced the termination of the "High-end Medical Consumables Industrialization Project" and plans to use the remaining raised funds to permanently supplement working capital [1][2][3] Group 1: Project Termination - The project was initially approved for a total fundraising of 750 million yuan through convertible bonds, with a net amount of 733 million yuan after expenses [2] - As of July 31, 2025, the project had accumulated an investment of 415 million yuan, representing 56.73% of the planned investment [2] - The decision to terminate the project was influenced by intensified market competition and declining profit margins, making the original profit expectations unattainable [3][4] Group 2: Financial Performance - The company has faced significant financial challenges, with a cumulative loss of nearly 400 million yuan over four and a half years [6] - Revenue figures from 2021 to 2024 were 1.79 billion yuan, 1.28 billion yuan, 1.19 billion yuan, and 1.44 billion yuan, showing a year-on-year decline of -21.04%, -28.74%, -6.49%, and an increase of 21.40% respectively [7] - In the first half of 2025, the company reported a revenue of 528 million yuan, a year-on-year decline of 16.38%, and a net loss of 7.76 million yuan, a significant drop of 155.31% compared to the previous year [7] Group 3: Asset Management and Regulatory Scrutiny - The company has been under regulatory scrutiny regarding the use of raised funds, with questions raised about the project's expected benefits and the authenticity of fund usage [4][5] - As of June 30, 2025, the total assets of the company were 3.542 billion yuan, with cash and cash equivalents amounting to 419 million yuan, a decrease of 17% from the beginning of the period [8]